Navigation Links
MolecularHealth and FDA to Collaborate on Analytical Tools for Mechanism-Based Drug Safety Assessment
Date:2/14/2012

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- MolecularHealth, Inc., a leader in clinico-molecular informatics™, today announced the establishment of a five-year research collaboration agreement with the U.S. Food and Drug Administration (FDA) to evaluate and refine MolecularHealth's Molecular Analysis of Side Effects (MASE), a software system intended to support mechanism-based drug safety assessment and prediction.

The FDA's Center for Drug Evaluation and Research (CDER) will work with MolecularHealth to incorporate non-proprietary molecular and clinical endpoints of regulatory interest into MASE, along with non-proprietary information on patient populations, drug promiscuity, molecular modes of action and mechanisms of disease.

"We are pleased to collaborate with the FDA to obtain their input into the evaluation of the analytical power of MASE for assessing drug safety in the U.S.," said Jeffrey D. Marrazzo, chief business officer of MolecularHealth. "MASE has the potential to benefit pharmaceutical developers, regulators and clinicians alike, helping them to develop and monitor drugs in a safer, more efficient manner."

MASE uses information about drug modes of action and the molecular implications of interacting treatments, co-morbidities and genetic profiles to enable a more precise assessment of drug safety. MASE enables the exploration and analysis of adverse event information from both statistical and molecular perspectives and provides analytical and visualization tools to support the detection and validation of drug-related safety issues.

"Drug safety monitoring and detection have become increasingly important and complex endeavors that depend heavily on a static, binary, observational system," said David Jackson, chief scientific officer of MolecularHealth. "We believe that MolecularHealth's predictive approach to understanding the molecular basis of adverse events will complement the agency's current mode of dru
'/>"/>

SOURCE MolecularHealth
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support
2. BioNeutral and Barnabas Health to Collaborate for Surgical Instrument Sterilization
3. Mercy/ROi and BD Collaborate to Improve Quality of Care and Reduce Costs
4. Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy
5. UCSF, Sanofi Collaborate to Find New Diabetes Cures
6. Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics
7. DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs
8. FDA, Austen BioInnovation Institute to Collaborate on the Safety and Performance of Materials used in Medical Devices
9. Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis
10. Biospace Lab Collaborates With ImaBio Group to Develop a Unique X-Ray Tomographic Module for its Preclinical Imaging System
11. Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
(Date:8/20/2014)... 2014 Trovagene, Inc. (NASDAQ:   TROV), a ... from two clinical studies will be presented at the ... diagnostic test for the detection of high risk strains ... to take place in Seattle ... Additionally, a new U.S. patent was issued earlier this ...
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... announces that a new market research report is ... Degeneration Therapy Area Pipeline Report ... Therapy Area Pipeline Report contains detailed information on ... insight into the pipeline status of macular degeneration ...
... Allscripts (NASDAQ: MDRX ) announced today that it ... March 31, 2011 after the stock market closes on Thursday, ... and webcast to discuss the company,s earnings and other information ... (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) More ...
Cached Medicine Technology:Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 2Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 2Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 4
(Date:8/20/2014)... have found a novel approach to treating cancer - ... edition of Science Translational Medicine shows that ... sent by nerves that are linked to cancer stem ... of Botox made the treatment cheap, safe and efficient. ... mice, and will soon start testing on humans. , ...
(Date:8/20/2014)... 2014 Quincy Bioscience, a Wisconsin-based biotech ... of the fastest growing private companies in the ... No. 2,941, Quincy Bioscience is honored again to be ... States. , Quincy Bioscience is manufacturer of Prevagen brand ... protein originally discovered in jellyfish and clinically shown to ...
(Date:8/20/2014)... DALLAS (PRWEB) August 20, 2014 Caddis ... track records of any healthcare real estate company in ... of medical assets valued at $500 million, including more ... of that significant growth, including expansions into new geographic ... expanded capabilities, company executives are pleased to announce an ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Braverman Eye ... the help of their experienced surgeons trained in PresbyLasik. ... to regain their lost or inaccurate vision. Their diligent ... Lasik surgery is making it possible for Presbyopia patients ... which occurs normally in people in the age group ...
(Date:8/20/2014)... August 20, 2014 Texas Medical Research Associates ... The study will help test the effectiveness of a new ... high cholesterol may be eligible to participate in the study. ... in the blood can lead to cardiovascular disease, the no. ... can help reduce the risk of heart disease and stroke. ...
Breaking Medicine News(10 mins):Health News:Treating gastric cancer -- with Botox 2Health News:Quincy Bioscience Recognized in Inc. 500|5000 List of America’s Fastest Growing Companies for Third Consecutive Year 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2Health News:Texas Medical Research Associates Announce New Study 2
... Jenifer Goodwin HealthDay Reporter , TUESDAY, June ... U.S. Preventive Services Task Force recommendations that women in ... and furious. Using email, social networking sites and electronic ... , Researchers say the magnitude of the reaction heralded ...
... have discovered a potent and highly-debilitating toxin in the ... is now prompting investigations of other marine mammals in ... by marine algae common on coral reefs, and accumulates ... the human disease caused by ciguatoxin, affects thousands of ...
... of Technology & Innovation, Proceedings of the National ... future and enormous need for stem cell therapeutics that ... deadly diseases. http://www.ingentaconnect.com/content/cog/ti/2011/00000013/00000001 ... replacement" procedures to restructure damaged organs, tissues and cells, ...
... IN THE ICU , Intensive care units are ... the future. A recent study, conducted by physicians from ... in New York, NY, studying 590 daytime admissions in ... can help address these staff shortages. In the ...
... consume an average of 13 hours of media content a ... according to a Northwestern University report, the first national study ... ethnicity. "In the past decade, the gap between minority ... and quadrupled for Hispanics," says Northwestern Professor Ellen Wartella, who ...
... Cincinnati (UC) Department of Emergency Medicine has received a ... to study the implementation of electronic health records in ... support the work of Michael Ward, MD, an assistant ... the past year focusing on simulation modeling in operations ...
Cached Medicine News:Health News:Is Social Networking Changing the Face of Medicine? 2Health News:Is Social Networking Changing the Face of Medicine? 3Health News:The future of stem cell applications challenging, bright 2Health News:Chest journal news briefs -- June 2011 issue 2Health News:Study: Stark differences in media use between minority and white youth 2Health News:Study: Stark differences in media use between minority and white youth 3Health News:Study: Stark differences in media use between minority and white youth 4Health News:Using simulation to model the implementation of electronic health records 2
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Medicine Products: